US FDA May Change Requirements For CV Outcomes Trials For Type 2 Diabetes Drugs

Endocrinologic and Metabolic Drugs Advisory Committee will reconsider 2008 guidance on evaluating CV risks in antidiabetic therapies at two-day meeting in October.

Diabetes

Ten years after a US FDA advisory committee called on the agency to require cardiovascular outcomes trials for all type 2 diabetes drug candidates, the agency is reconvening the panel, apparently to consider the ongoing need for, and design of, these studies.

In a Federal Register notice scheduled for publication Sept. 18, FDA announced that the Endocrinologic and Metabolic Drugs Advisory...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers